Annual Meeting News

CARLSBAD, Calif.--(BUSINESS WIRE)--Arima Genomics, a company leveraging whole-genome sequence and structure information, today announced new data to be presented at ASH....

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca advances its ambition to redefine hematology care with new data from its diverse pipeline and portfolio at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6-9, 2025. This year’s ASH congress will feature the Company’s largest presence to date, with 65 abstracts across eight approved and investigational medicines, including 15 oral presentations. Key presentations include: Phase I trial of surovatamig: Updated r...

LONDON--(BUSINESS WIRE)--Rio Tinto will today outline its strategy to deliver industry leading returns by becoming stronger, sharper and simpler, at its 2025 Capital Markets Day. Chief Executive Simon Trott and members of the executive team will detail how Rio Tinto will unlock its full potential to become the most valued metals and mining business through a strategy that starts with having the right assets in the right markets, supported by a diversified model that delivers market-leading perf...

ATLANTA--(BUSINESS WIRE)--Operation HOPE, a national nonprofit dedicated to helping low- and moderate-income Americans thrive in an ever-changing economy, today announced the release of the 2025 Annual Report of its AI Ethics Council (AIEC), marking a historic year of moving from conversation to execution in the pursuit of ethical, inclusive artificial intelligence that serves all communities. The report was announced at the Annual Meeting of the Hope Global Forums in Atlanta this week. Co-chai...

WASHINGTON--(BUSINESS WIRE)--The ASH Research Collaborative will present new data at the 67th ASH Annual Meeting and Exposition that feature findings from its research networks....

LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will present eight posters at the American Epilepsy Society (AES) Annual Meeting, taking place Dec. 5-9 in Atlanta. These presentations highlight real-world evidence from the CORE-VNS study, the largest prospective, multinational observational study of VNS Therapy™ for Drug-Resistant Epilepsy (DRE), and new health economics analyses. “At the heart of LivaNova’s purpose as a Comp...

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced the publication of positive results from a Phase 2 study of safusidenib, a novel, oral, potent, brain-penetrant targeted inhibitor of mutant IDH1, in patients with chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutant gliomas. The findings were first published online on November 8 in the journal of Neuro-Oncology. “Until...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, announced that new data on Signatera will be presented at the 2025 American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, Florida. Natera and its collaborators will present four abstracts highlighting the clinical validity and utility of Signatera in hematologic malignancies. The datasets include an oral presentation on a retrospective...

SCHAUMBURG, Ill. & PARSIPPANY, N.J.--(BUSINESS WIRE)--The Society of Urologic Oncology (SUO) and Ferring Pharmaceuticals today announced the SUO NMIBC (non-muscle invasive bladder cancer) Fellows Research Grant, created to support outstanding clinical research investigators committed to advancing the understanding and treatment of NMIBC. Two applicants will receive the SUO NMIBC Fellows Research Grant, provided by an educational grant from Ferring Pharmaceuticals. “Advancing research in NMIBC i...

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that it will highlight new open-label extension data from the company’s investigation of EPX-100 (clemizole hydrochloride) in the ongoing Phase 3 ARGUS trial for the treatment of Dravet syndrome at the 2025 American Epilepsy Society (AES) Annual Meeting being held December 5 – December 9, 2025, in Atlanta, GA. The ARGUS trial is currently enrolling, and more information can be found at arg...